Buy BPC-157 Research Peptide

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide based on a sequence found in a protein in gastric juice. It is studied in animal research for its effects on the healing and repair of tissues such as tendon, muscle and gut lining.

• A 15-amino-acid peptide based on a sequence from a protein found in the stomach
• Studied in rat research for its effects on the healing of tendon, muscle and gut tissue
• Investigated in cell and animal studies for its effects on blood-vessel growth and the nitric oxide pathway
• Studied for how it interacts with the body’s own protective (prostaglandin) system

For research use only. Not approved for human therapeutic use.

BPC-157 (CAS 137525-51-0), also known as Body Protection Compound-157, Bepecin, and PL 14736, is a synthetic pentadecapeptide with the molecular formula C₆₂H₉₈N₁₆O₂₂ and a molecular weight of 1419.55 g/mol. Defined by the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, BPC-157 corresponds to a partial sequence of a larger protein (BPC) first isolated from human gastric juice. Notably, the compound is stable across a wide pH range and fully soluble in aqueous media, unusual properties for a peptide of this size that are attributed to its high proportion of proline and charged residues. Produced via solid-phase peptide synthesis, BPC-157 is associated with nitric oxide (NO) signalling, VEGF expression, and FAK-paxillin pathway.

BPC-157 is one of the most extensively referenced cytoprotective peptides, with studies spanning gastrointestinal, musculoskeletal, cardiovascular, and central nervous system research contexts. In vitro studies have examined its interaction with endothelial cell migration, fibroblast proliferation, and nitric oxide synthase (NOS) system modulation, documenting activation of the VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS signalling axes in vascular endothelial cells [1]. Tendon fibroblast studies have additionally documented BPC-157 upregulation of growth hormone receptor (GHR) expression, a receptor that signals canonically through the JAK2-STAT pathway [2]. In vivo rodent studies have investigated BPC-157 across gastrointestinal ulcer models, tendon and ligament transection models, and peripheral nerve injury paradigms, with research examining angiogenesis and new-vessel and granulation-tissue formation in both gastrointestinal mucosa and musculoskeletal tissue [3][4], alongside collagen deposition kinetics and, in a separate body of central nervous system work, dopaminergic and serotonergic system dynamics, following both systemic and local administration.

BPC-157 is manufactured in an ISO9001 certified laboratory to a guaranteed purity of ≥98%. Every batch is independently tested using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system to preserve compound integrity throughout the supply chain. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017 Mar;95(3):323-33. .PubMed PMID: 278479662Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014 Nov 19;19(11):19066-77. .PubMed PMID: 254154723Sikiric P, Separovic J, Anic T, Buljat G, Mikus D, Seiwerth S, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. Journal of Physiology-Paris. 1999 Dec 1;93(6):479-85.doi:10.1016/S0928-4257(99)00123-04Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009 Dec;60 Suppl 7:191-6. .PubMed PMID: 20388964

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

BPC-157 (CAS 137525-51-0), also known as Body Protection Compound-157, Bepecin, and PL 14736, is a synthetic pentadecapeptide with the molecular formula C₆₂H₉₈N₁₆O₂₂ and a molecular weight of 1419.55 g/mol. Defined by the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, BPC-157 corresponds to a partial sequence of a larger protein (BPC) first isolated from human gastric juice. Notably, the compound is stable across a wide pH range and fully soluble in aqueous media, unusual properties for a peptide of this size that are attributed to its high proportion of proline and charged residues. Produced via solid-phase peptide synthesis, BPC-157 is associated with nitric oxide (NO) signalling, VEGF expression, and FAK-paxillin pathway.

BPC-157 is one of the most extensively referenced cytoprotective peptides, with studies spanning gastrointestinal, musculoskeletal, cardiovascular, and central nervous system research contexts. In vitro studies have examined its interaction with endothelial cell migration, fibroblast proliferation, and nitric oxide synthase (NOS) system modulation, documenting activation of the VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS signalling axes in vascular endothelial cells [1]. Tendon fibroblast studies have additionally documented BPC-157 upregulation of growth hormone receptor (GHR) expression, a receptor that signals canonically through the JAK2-STAT pathway [2]. In vivo rodent studies have investigated BPC-157 across gastrointestinal ulcer models, tendon and ligament transection models, and peripheral nerve injury paradigms, with research examining angiogenesis and new-vessel and granulation-tissue formation in both gastrointestinal mucosa and musculoskeletal tissue [3][4], alongside collagen deposition kinetics and, in a separate body of central nervous system work, dopaminergic and serotonergic system dynamics, following both systemic and local administration.

BPC-157 is manufactured in an ISO9001 certified laboratory to a guaranteed purity of ≥98%. Every batch is independently tested using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system to preserve compound integrity throughout the supply chain. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017 Mar;95(3):323-33. .PubMed PMID: 278479662Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014 Nov 19;19(11):19066-77. .PubMed PMID: 254154723Sikiric P, Separovic J, Anic T, Buljat G, Mikus D, Seiwerth S, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. Journal of Physiology-Paris. 1999 Dec 1;93(6):479-85.doi:10.1016/S0928-4257(99)00123-04Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009 Dec;60 Suppl 7:191-6. .PubMed PMID: 20388964

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number137525-51-0Molecular Weight1,419.55 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUBPC157

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

BPC-157 (CAS 137525-51-0), also known as Body Protection Compound-157, Bepecin, and PL 14736, is a synthetic pentadecapeptide with the molecular formula C₆₂H₉₈N₁₆O₂₂ and a molecular weight of 1419.55 g/mol. Defined by the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, BPC-157 corresponds to a partial sequence of a larger protein (BPC) first isolated from human gastric juice. Notably, the compound is stable across a wide pH range and fully soluble in aqueous media, unusual properties for a peptide of this size that are attributed to its high proportion of proline and charged residues. Produced via solid-phase peptide synthesis, BPC-157 is associated with nitric oxide (NO) signalling, VEGF expression, and FAK-paxillin pathway.

BPC-157 is one of the most extensively referenced cytoprotective peptides, with studies spanning gastrointestinal, musculoskeletal, cardiovascular, and central nervous system research contexts. In vitro studies have examined its interaction with endothelial cell migration, fibroblast proliferation, and nitric oxide synthase (NOS) system modulation, documenting activation of the VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS signalling axes in vascular endothelial cells [1]. Tendon fibroblast studies have additionally documented BPC-157 upregulation of growth hormone receptor (GHR) expression, a receptor that signals canonically through the JAK2-STAT pathway [2]. In vivo rodent studies have investigated BPC-157 across gastrointestinal ulcer models, tendon and ligament transection models, and peripheral nerve injury paradigms, with research examining angiogenesis and new-vessel and granulation-tissue formation in both gastrointestinal mucosa and musculoskeletal tissue [3][4], alongside collagen deposition kinetics and, in a separate body of central nervous system work, dopaminergic and serotonergic system dynamics, following both systemic and local administration.

BPC-157 is manufactured in an ISO9001 certified laboratory to a guaranteed purity of ≥98%. Every batch is independently tested using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system to preserve compound integrity throughout the supply chain. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017 Mar;95(3):323-33. .PubMed PMID: 278479662Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014 Nov 19;19(11):19066-77. .PubMed PMID: 254154723Sikiric P, Separovic J, Anic T, Buljat G, Mikus D, Seiwerth S, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. Journal of Physiology-Paris. 1999 Dec 1;93(6):479-85.doi:10.1016/S0928-4257(99)00123-04Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009 Dec;60 Suppl 7:191-6. .PubMed PMID: 20388964

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number137525-51-0Molecular Weight1,419.55 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUBPC157

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.